Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linagliptin + dapagliflozin
- Development stage
- Discontinued
- Lead developer
- EMS
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LIMA is a fixed-dose combination (FDC) therapy developed by the Brazilian pharmaceutical company EMS for the treatment of type 2 diabetes mellitus. It consists of linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Linagliptin works by slowing the inactivation of incretin hormones, such as glucagon-like peptide-1 (GLP-1), which increases insulin secretion and decreases glucagon levels in a glucose-dependent manner. Dapagliflozin reduces renal glucose reabsorption in the proximal tubule of the kidney, leading to increased urinary glucose excretion and a reduction in blood glucose levels. By combining these two agents with complementary mechanisms of action, LIMA aims to provide superior glycemic control compared to monotherapy. The combination has been evaluated in Phase 3 clinical trials (e.g., NCT04121130) comparing its efficacy and safety against the individual components.
- Brand names
- Lina Dapa
- Other names
- LIMA associationlinagliptin/dapagliflozin fixed-dose combination
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)DPP8 (Dipeptidyl peptidase 8)DPP9 (Dipeptidyl Peptidase 9)FAP (Fibroblast activation protein alpha)SLC5A1 (Sodium Glucose Cotransporter 1)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on linagliptin + dapagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linagliptin + dapagliflozin.